Merck’s Cavalier Attitude Toward the Welfare of HIV/HCV-Coinfected Patients by Tracy Swan In places where access to antiretroviral therapy is widespread, people living with HIV are now dying from a common and curable coinfection: hepatitis C virus (HCV). HIV increases…
TAG at 20: Early Campaigns; The Odyssey of Therapeutic Vaccines for HIV; What You Don’t Know, You Can Sell; Does Obama’s 2013 Budget Herald the End of PEPFAR?; Childhood TB Advocacy Picks Up Steam
The Hepatitis C Community Advisory Board (HCAB) recognizes the value of more effective and less toxic treatment for hepatitis C virus (HCV).
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
By Coco Jervis and Sue Perez Negligible Increases for AIDS, TB, Viral Hepatitis Treatment and Research On Monday, February 1, 2010, President Barack Obama unveiled his fiscal year (FY) 2011 budget to the U.S. Congress. Global health programs were allocated…
By Tracy Swan and Lei Chou Background: In the United States, the highest all-cause mortality rates are found among African American men and women aged 25 to 64. This racial disparity is underscored by a disproportionate burden of viral hepatitis…
HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development Second Edition September 2011 Written by Polly Clayden, Simon Collins, Mark Harrington, Richard Jefferys, Tracy Swan, Javid Syed, and Claire Wingfield with a a contribution…
The new drug, diagnostic, and vaccine pipeline has never looked more promising for people with HIV, hepatitis C virus (HCV), and tuberculosis (TB), according to a report released today by Treatment Action Group (TAG) and HIV i-Base.
February 7, 2011 Dear Secretary Clinton, We write to ask for your leadership in ensuring The Global Fund to Fight AIDS, TB, and Malaria is “open for new business,” saving lives through expanding programming in 2012. We ask that you…